caspofungin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antifungal antibiotics 2977 162808-62-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • caspofungin acetate
  • caspofungin diacetate
  • cancidas
  • caspofungin
  • MK-0991
Caspofungin, an echinocandin, inhibits the synthesis of beta (1,3)-D-glucan, an essential component of the cell wall of susceptible Aspergillus species and Candida species. Beta (1,3)-D-glucan is not present in mammalian cells. Caspofungin has shown activity against Candida species and in regions of active cell growth of the hyphae of Aspergillus fumigatus.
  • Molecular weight: 1093.33
  • Formula: C52H88N10O15
  • CLOGP: -2.35
  • LIPINSKI: 3
  • HAC: 25
  • HDO: 16
  • TPSA: 412.03
  • ALOGS: -3.47
  • ROTB: 23

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1.40 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.91 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.13 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.14 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 27 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 15 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Jan. 26, 2001 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Systemic mycosis 256.85 27.97 53 8123 1144 63479702
Septic shock 230.11 27.97 129 8047 66500 63414346
Multiple organ dysfunction syndrome 226.72 27.97 121 8055 56631 63424215
Bronchopulmonary aspergillosis 176.63 27.97 59 8117 8576 63472270
Upper respiratory fungal infection 164.00 27.97 27 8149 151 63480695
Drug resistance 145.36 27.97 67 8109 22866 63457980
Drug ineffective 136.13 27.97 364 7812 1044401 62436445
Mucormycosis 129.27 27.97 36 8140 2835 63478011
Aspergillus infection 125.60 27.97 45 8131 8048 63472798
Diffuse large B-cell lymphoma refractory 122.30 27.97 29 8147 1201 63479645
Cholestasis 120.90 27.97 64 8112 29370 63451476
Systemic candida 120.47 27.97 35 8141 3210 63477636
Drug reaction with eosinophilia and systemic symptoms 115.25 27.97 65 8111 33771 63447075
Toxic epidermal necrolysis 112.37 27.97 58 8118 25276 63455570
Fusarium infection 100.82 27.97 22 8154 624 63480222
Febrile neutropenia 94.41 27.97 95 8081 118354 63362492
Venoocclusive liver disease 86.93 27.97 30 8146 4805 63476041
Pathogen resistance 85.99 27.97 32 8144 6366 63474480
Alternaria infection 83.32 27.97 16 8160 235 63480611
Cerebral aspergillosis 80.75 27.97 17 8159 405 63480441
Acute respiratory distress syndrome 79.54 27.97 45 8131 23489 63457357
Candida infection 76.86 27.97 47 8129 28304 63452542
Fatigue 73.73 27.97 13 8163 888015 62592831
Cytomegalovirus infection 73.35 27.97 41 8135 20911 63459935
Geotrichum infection 73.18 27.97 16 8160 458 63480388
Candida sepsis 69.97 27.97 19 8157 1361 63479485
Hepatocellular injury 68.17 27.97 43 8133 27338 63453508
Neutropenia 67.46 27.97 97 8079 174908 63305938
Disseminated intravascular coagulation 65.93 27.97 37 8139 19014 63461832
Fungal infection 65.60 27.97 47 8129 36827 63444019
Sepsis 65.14 27.97 89 8087 153034 63327812
Graft versus host disease 63.21 27.97 26 8150 6737 63474109
Toxic skin eruption 61.47 27.97 31 8145 12854 63467992
Fungaemia 59.56 27.97 19 8157 2384 63478462
Fungal sepsis 57.51 27.97 16 8160 1254 63479592
Product use in unapproved indication 54.52 27.97 89 8087 178991 63301855
Graft versus host disease in gastrointestinal tract 53.99 27.97 19 8157 3222 63477624
Adenoviral hepatitis 53.44 27.97 12 8164 389 63480457
Acute graft versus host disease 51.74 27.97 20 8156 4408 63476438
Respiratory failure 50.71 27.97 64 8112 101794 63379052
Thrombocytopenia 49.94 27.97 78 8098 151079 63329767
Capillary leak syndrome 48.84 27.97 16 8160 2184 63478662
Hepatic cytolysis 48.14 27.97 28 8148 15379 63465467
Hepatic failure 46.97 27.97 38 8138 35618 63445228
Enterococcal infection 46.81 27.97 22 8154 7826 63473020
Pyelonephritis fungal 46.44 27.97 9 8167 139 63480707
Acute kidney injury 44.50 27.97 102 8074 263313 63217533
Pain 44.49 27.97 20 8156 740608 62740238
Perinephric abscess 43.34 27.97 9 8167 200 63480646
Infective aneurysm 42.52 27.97 10 8166 399 63480447
Adenovirus infection 41.27 27.97 16 8160 3555 63477291
Dizziness 41.02 27.97 4 8172 429921 63050925
Emphysematous pyelonephritis 40.82 27.97 9 8167 268 63480578
Pancytopenia 40.66 27.97 56 8120 96877 63383969
Drug level decreased 40.56 27.97 20 8156 7899 63472947
Pseudomonas infection 39.39 27.97 22 8154 11191 63469655
Dilatation intrahepatic duct acquired 37.39 27.97 10 8166 676 63480170
Hepatic necrosis 37.21 27.97 17 8159 5670 63475176
Brain oedema 37.10 27.97 23 8153 14172 63466674
Eosinophilia 35.92 27.97 27 8149 22729 63458117
Staphylococcal scalded skin syndrome 35.22 27.97 7 8169 124 63480722
Trichosporon infection 34.92 27.97 8 8168 284 63480562
Venous haemorrhage 34.79 27.97 8 8168 289 63480557
Cerebral haemorrhage 34.77 27.97 30 8146 30699 63450147
Cytokine release syndrome 34.42 27.97 22 8154 14292 63466554
Liver abscess 33.73 27.97 13 8163 2841 63478005
Stevens-Johnson syndrome 33.72 27.97 27 8149 24923 63455923
Headache 33.67 27.97 20 8156 633221 62847625
Peritonitis 33.12 27.97 23 8153 17131 63463715
Abscess fungal 32.85 27.97 6 8170 66 63480780
Epidermolysis 32.80 27.97 9 8167 670 63480176
Haemophagocytic lymphohistiocytosis 32.37 27.97 19 8157 10608 63470238
Dyspnoea 32.29 27.97 23 8153 661290 62819556
Arthralgia 31.70 27.97 17 8159 569693 62911153
Drug level increased 31.57 27.97 25 8151 22711 63458135
Renal failure 31.16 27.97 55 8121 117597 63363249
Fungal endocarditis 30.91 27.97 7 8169 236 63480610
Nausea 30.90 27.97 39 8137 854432 62626414
Mucosal inflammation 30.82 27.97 34 8142 46894 63433952
Abdominal discomfort 30.55 27.97 3 8173 320882 63159964
Blood culture positive 30.49 27.97 14 8162 4721 63476125
Drug level below therapeutic 30.13 27.97 14 8162 4852 63475994
Graft versus host disease in skin 30 27.97 12 8164 2893 63477953
Hepatotoxicity 29.97 27.97 30 8146 37011 63443835
Fungal test positive 29.72 27.97 8 8168 554 63480292
Scedosporium infection 29.71 27.97 8 8168 555 63480291
Agranulocytosis 29.37 27.97 25 8151 25109 63455737
Drug hypersensitivity 29.32 27.97 3 8173 310684 63170162
Hyperbilirubinaemia 28.73 27.97 18 8158 11296 63469550
Pyrexia 28.61 27.97 128 8048 470350 63010496
Graft versus host disease in liver 28.48 27.97 8 8168 649 63480197
Shock haemorrhagic 28.33 27.97 17 8159 9878 63470968
Leukoencephalopathy 28.27 27.97 13 8163 4400 63476446

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 326.13 22.54 537 10345 456214 34489835
Multiple organ dysfunction syndrome 212.97 22.54 182 10700 76384 34869665
Aspergillus infection 208.20 22.54 93 10789 12161 34933888
Systemic mycosis 205.30 22.54 55 10827 1518 34944531
Drug resistance 201.79 22.54 116 10766 25811 34920238
Bronchopulmonary aspergillosis 153.94 22.54 80 10802 14579 34931470
Septic shock 139.80 22.54 140 10742 71694 34874355
Pathogen resistance 139.11 22.54 65 10817 9417 34936632
Dysplastic naevus 138.89 22.54 32 10850 464 34945585
Solar lentigo 135.65 22.54 32 10850 517 34945532
Photodermatosis 134.85 22.54 32 10850 531 34945518
Central nervous system fungal infection 121.98 22.54 27 10855 323 34945726
Candida infection 96.12 22.54 63 10819 17652 34928397
Fungaemia 83.24 22.54 31 10851 2537 34943512
Drug reaction with eosinophilia and systemic symptoms 78.62 22.54 72 10810 32940 34913109
Respiratory failure 75.32 22.54 127 10755 108445 34837604
Febrile neutropenia 74.46 22.54 144 10738 136705 34809344
Mucormycosis 72.77 22.54 36 10846 5906 34940143
Fungal infection 70.58 22.54 50 10832 15885 34930164
Actinic keratosis 69.11 22.54 32 10850 4535 34941514
Fusarium infection 68.79 22.54 22 10860 1138 34944911
Venoocclusive disease 65.98 22.54 27 10855 2840 34943209
Agranulocytosis 64.74 22.54 56 10826 23765 34922284
Sepsis 59.51 22.54 148 10734 166413 34779636
Systemic candida 59.17 22.54 27 10855 3699 34942350
Product use in unapproved indication 57.09 22.54 118 10764 117381 34828668
Fatigue 55.69 22.54 23 10859 370630 34575419
Nephrogenic diabetes insipidus 54.26 22.54 19 10863 1302 34944747
Cerebral aspergillosis 52.76 22.54 19 10863 1413 34944636
Differentiation syndrome 52.68 22.54 19 10863 1419 34944630
Cytomegalovirus infection 50.83 22.54 51 10831 26084 34919965
Enterococcal infection 50.22 22.54 33 10849 9273 34936776
Dizziness 50.16 22.54 5 10877 218516 34727533
Photosensitivity reaction 48.67 22.54 34 10848 10560 34935489
Hypokalaemia 48.38 22.54 74 10808 58140 34887909
Toxic epidermal necrolysis 45.36 22.54 44 10838 21602 34924447
Aortoenteric fistula 45.22 22.54 10 10872 119 34945930
Incision site pain 44.66 22.54 18 10864 1820 34944229
Cholestasis 44.19 22.54 48 10834 26900 34919149
Dyspnoea 44.06 22.54 32 10850 376750 34569299
Fall 43.19 22.54 6 10876 202879 34743170
Graft versus host disease in skin 42.84 22.54 22 10860 3903 34942146
Squamous cell carcinoma of skin 41.06 22.54 31 10851 10850 34935199
Geotrichum infection 40.21 22.54 12 10870 492 34945557
Lymphocyte count decreased 40.10 22.54 42 10840 22580 34923469
Endocarditis 39.86 22.54 25 10857 6486 34939563
Hyperleukocytosis 39.84 22.54 17 10865 1985 34944064
Trichosporon infection 39.77 22.54 13 10869 721 34945328
Graft versus host disease 39.63 22.54 30 10852 10539 34935510
Nausea 37.01 22.54 31 10851 339877 34606172
Pancytopenia 36.51 22.54 87 10795 95070 34850979
Splenic infection fungal 36.51 22.54 8 10874 91 34945958
Haemophagocytic lymphohistiocytosis 36.25 22.54 31 10851 12942 34933107
Organ failure 35.89 22.54 16 10866 2075 34943974
Weight decreased 35.71 22.54 6 10876 176295 34769754
Graft versus host disease in gastrointestinal tract 35.51 22.54 19 10863 3664 34942385
Pseudomonas infection 35.45 22.54 30 10852 12352 34933697
Electrocardiogram QT prolonged 35.34 22.54 53 10829 40899 34905150
Asthenia 33.97 22.54 17 10865 245234 34700815
Arthralgia 33.97 22.54 6 10876 170035 34776014
Encephalopathy 33.80 22.54 48 10834 35271 34910778
Lower respiratory tract infection fungal 33.71 22.54 11 10871 607 34945442
Bone marrow failure 32.91 22.54 43 10839 29210 34916839
Rectal perforation 32.19 22.54 10 10872 470 34945579
Acute respiratory distress syndrome 32.09 22.54 40 10842 25929 34920120
Mucosal inflammation 31.93 22.54 49 10833 38573 34907476
Pain 31.80 22.54 12 10870 204663 34741386
Red blood cells urine positive 31.56 22.54 14 10868 1795 34944254
Toxic skin eruption 31.39 22.54 27 10855 11358 34934691
Pulmonary mucormycosis 31.15 22.54 11 10871 772 34945277
Transaminases increased 31.06 22.54 40 10842 26783 34919266
Decreased appetite 30.88 22.54 7 10875 166385 34779664
Hepatic failure 30.24 22.54 45 10837 34486 34911563
Fungal endocarditis 30.11 22.54 9 10873 371 34945678
Systemic inflammatory response syndrome 29.58 22.54 21 10861 6688 34939361
Protein urine present 29.33 22.54 19 10863 5209 34940840
Vomiting 28.92 22.54 21 10861 247600 34698449
Hyperbilirubinaemia 27.60 22.54 30 10852 16813 34929236
Haemodynamic instability 27.11 22.54 23 10859 9500 34936549
Spinal cord disorder 26.47 22.54 10 10872 851 34945198
Cytokine release syndrome 26.31 22.54 34 10848 22843 34923206
Hypogonadism 25.65 22.54 13 10869 2242 34943807
Malaise 25.53 22.54 13 10869 185812 34760237
Scopulariopsis infection 25.09 22.54 6 10876 103 34945946
Chimerism 24.77 22.54 7 10875 236 34945813
Off label use 24.65 22.54 218 10664 419306 34526743
Venoocclusive liver disease 24.25 22.54 20 10862 7946 34938103
Procedural pain 23.42 22.54 16 10866 4790 34941259
Hypoperfusion 23.39 22.54 10 10872 1173 34944876
Hepatotoxicity 23.26 22.54 31 10851 21454 34924595
Klebsiella infection 23.05 22.54 20 10862 8511 34937538

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug ineffective 495.60 22.72 877 17257 1080036 78646218
Systemic mycosis 447.46 22.72 107 18027 2559 79723695
Multiple organ dysfunction syndrome 384.18 22.72 273 17861 119973 79606281
Bronchopulmonary aspergillosis 336.81 22.72 142 17992 22152 79704102
Aspergillus infection 316.23 22.72 130 18004 19031 79707223
Septic shock 301.12 22.72 238 17896 122563 79603691
Pathogen resistance 205.44 22.72 88 18046 14254 79712000
Drug resistance 195.57 22.72 121 18013 42092 79684162
Mucormycosis 169.30 22.72 66 18068 8403 79717851
Drug reaction with eosinophilia and systemic symptoms 169.14 22.72 130 18004 64114 79662140
Systemic candida 165.65 22.72 61 18073 6645 79719609
Candida infection 163.09 22.72 104 18030 38110 79688144
Febrile neutropenia 157.13 22.72 226 17908 230773 79495481
Upper respiratory fungal infection 153.58 22.72 31 18103 324 79725930
Dysplastic naevus 143.07 22.72 32 18102 563 79725691
Toxic epidermal necrolysis 141.55 22.72 101 18033 44480 79681774
Cholestasis 129.65 22.72 102 18032 52007 79674247
Fusarium infection 129.46 22.72 37 18097 1795 79724459
Photodermatosis 127.72 22.72 32 18102 932 79725322
Respiratory failure 125.87 22.72 179 17955 180732 79545522
Fatigue 125.74 22.72 29 18105 929698 78796556
Solar lentigo 122.59 22.72 32 18102 1101 79725153
Central nervous system fungal infection 117.53 22.72 26 18108 434 79725820
Fungaemia 114.26 22.72 42 18092 4549 79721705
Cytomegalovirus infection 113.75 22.72 87 18047 42557 79683697
Graft versus host disease 112.58 22.72 59 18075 14967 79711287
Geotrichum infection 107.55 22.72 28 18106 953 79725301
Sepsis 104.43 22.72 205 17929 269223 79457031
Fungal infection 95.90 22.72 78 18056 41670 79684584
Product use in unapproved indication 93.99 22.72 188 17946 250171 79476083
Venoocclusive liver disease 93.29 22.72 48 18086 11723 79714531
Acute respiratory distress syndrome 92.21 22.72 78 18056 43989 79682265
Enterococcal infection 88.37 22.72 51 18083 15609 79710645
Dizziness 87.76 22.72 9 18125 526432 79199822
Venoocclusive disease 85.64 22.72 34 18100 4539 79721715
Agranulocytosis 84.70 22.72 75 18059 44955 79681299
Cerebral aspergillosis 82.42 22.72 26 18108 1770 79724484
Pancytopenia 80.38 22.72 139 17995 165606 79560648
Pain 78.62 22.72 31 18103 703771 79022483
Dyspnoea 77.45 22.72 50 18084 856975 78869279
Toxic skin eruption 76.53 22.72 53 18081 22240 79704014
Nausea 71.18 22.72 68 18066 957128 78769126
Haemophagocytic lymphohistiocytosis 70.49 22.72 50 18084 21787 79704467
Actinic keratosis 70.14 22.72 32 18102 6010 79720244
Trichosporon infection 69.62 22.72 20 18114 988 79725266
Arthralgia 69.27 22.72 22 18112 571781 79154473
Fall 68.18 22.72 14 18120 487615 79238639
Hepatocellular injury 67.89 22.72 68 18066 47525 79678729
Pseudomonas infection 67.80 22.72 48 18086 20855 79705399
Hepatic failure 67.03 22.72 76 18058 61136 79665118
Headache 66.37 22.72 33 18101 653739 79072515
Candida sepsis 62.57 22.72 23 18111 2490 79723764
Bone marrow failure 60.33 22.72 66 18068 51041 79675213
Cytokine release syndrome 59.93 22.72 56 18078 35942 79690312
Differentiation syndrome 58.80 22.72 22 18112 2502 79723752
Alternaria infection 58.34 22.72 16 18118 666 79725588
Acute graft versus host disease 57.07 22.72 33 18101 10134 79716120
Incision site pain 56.36 22.72 22 18112 2808 79723446
Systemic inflammatory response syndrome 55.95 22.72 34 18100 11431 79714823
Electrocardiogram QT prolonged 54.92 22.72 84 18050 90302 79635952
Nephrogenic diabetes insipidus 54.87 22.72 20 18114 2114 79724140
Encephalopathy 54.81 22.72 72 18062 67325 79658929
Disseminated intravascular coagulation 54.43 22.72 53 18081 35789 79690465
Organ failure 52.04 22.72 23 18111 4010 79722244
Vomiting 50.92 22.72 46 18088 665782 79060472
Graft versus host disease in gastrointestinal tract 50.60 22.72 26 18108 6330 79719924
Hyperbilirubinaemia 50.46 22.72 43 18091 24475 79701779
Weight decreased 50.02 22.72 10 18124 355188 79371066
Mucosal inflammation 49.85 22.72 73 18061 75507 79650747
Eosinophilia 49.13 22.72 56 18078 45289 79680965
Adenovirus infection 48.96 22.72 28 18106 8419 79717835
Malaise 47.77 22.72 26 18108 489843 79236411
Red blood cells urine positive 47.48 22.72 23 18111 4940 79721314
Aortoenteric fistula 46.65 22.72 10 18124 143 79726111
Transaminases increased 46.35 22.72 58 18076 51685 79674569
Staphylococcal scalded skin syndrome 46.30 22.72 12 18122 401 79725853
Graft versus host disease in skin 45.92 22.72 24 18110 6049 79720205
Asthenia 45.90 22.72 30 18104 511659 79214595
Hypokalaemia 45.62 22.72 101 18033 143939 79582315
Abdominal discomfort 45.26 22.72 3 18131 250724 79475530
Hepatotoxicity 45.10 22.72 57 18077 51295 79674959
Hepatic function abnormal 43.08 22.72 67 18067 73040 79653214
Abscess fungal 42.99 22.72 11 18123 349 79725905
Fungal sepsis 42.81 22.72 16 18118 1814 79724440
Squamous cell carcinoma of skin 42.69 22.72 31 18103 14002 79712252
Renal failure 42.67 22.72 121 18013 200847 79525407
Drug interaction 42.60 22.72 197 17937 414986 79311268
Lymphocyte count decreased 42.34 22.72 53 18081 47236 79679018
Scedosporium infection 42.32 22.72 15 18119 1463 79724791
Klebsiella infection 41.74 22.72 32 18102 15688 79710566
Lower respiratory tract infection fungal 41.35 22.72 13 18121 875 79725379
Photosensitivity reaction 41.34 22.72 36 18098 21091 79705163
Rash maculo-papular 41.16 22.72 57 18077 56021 79670233
Alopecia 41.09 22.72 3 18131 231352 79494902
Drug hypersensitivity 40.87 22.72 9 18125 298907 79427347
Endocarditis 40.67 22.72 27 18107 10570 79715684
Hyperleukocytosis 40.63 22.72 17 18117 2593 79723661
Chimerism 40.08 22.72 10 18124 286 79725968
Infective aneurysm 39.73 22.72 13 18121 995 79725259
Fungal test positive 38.66 22.72 13 18121 1083 79725171
Acute kidney injury 38.43 22.72 225 17909 519179 79207075
Swelling 37.94 22.72 3 18131 216708 79509546
Drug level below therapeutic 37.75 22.72 25 18109 9745 79716509
Splenic infection fungal 37.68 22.72 8 18126 109 79726145
Drug level decreased 37.54 22.72 29 18105 14373 79711881
Off label use 37.18 22.72 341 17793 906874 78819380
Pyelonephritis fungal 37.04 22.72 9 18125 230 79726024
Protein urine present 36.97 22.72 25 18109 10087 79716167
Stevens-Johnson syndrome 36.84 22.72 45 18089 39121 79687133
Adenoviral hepatitis 36.72 22.72 12 18122 915 79725339
Decreased appetite 36.65 22.72 16 18118 342402 79383852
Weight increased 36.64 22.72 9 18125 277377 79448877
Hepatitis fulminant 36.63 22.72 22 18112 7240 79719014
Perinephric abscess 36.19 22.72 9 18125 254 79726000
Drug intolerance 36.01 22.72 8 18126 264111 79462143
Neutropenia 35.20 22.72 144 17990 287566 79438688
Pruritus 34.21 22.72 24 18110 394624 79331630
Cerebral haemorrhage 34.18 22.72 53 18081 57620 79668634
Pulmonary mucormycosis 34.03 22.72 12 18122 1153 79725101
Emphysematous pyelonephritis 33.61 22.72 9 18125 342 79725912
Infusion related reaction 33.42 22.72 6 18128 230231 79496023
Gait disturbance 33.37 22.72 4 18130 207502 79518752
Fungal endocarditis 32.86 22.72 10 18124 604 79725650
BK virus infection 32.74 22.72 22 18112 8782 79717472
Pain in extremity 31.82 22.72 22 18112 364516 79361738
Blood pressure increased 31.80 22.72 5 18129 211355 79514899
Leukopenia 31.71 22.72 77 18057 116436 79609818
Drug ineffective for unapproved indication 31.64 22.72 48 18086 51190 79675064
Neutrophil count increased 31.32 22.72 36 18098 29360 79696894
Shock haemorrhagic 31.09 22.72 30 18104 20030 79706224
Dilatation intrahepatic duct acquired 31.05 22.72 10 18124 728 79725526
Anxiety 31.04 22.72 9 18125 248503 79477751
Disseminated mucormycosis 30.91 22.72 10 18124 738 79725516
Depression 30.71 22.72 6 18128 216784 79509470
Insomnia 30.40 22.72 9 18125 245161 79481093
Pneumonia fungal 30.15 22.72 23 18111 11187 79715067
Drug level increased 30.14 22.72 41 18093 39610 79686644
Rectal perforation 29.04 22.72 10 18124 895 79725359
Venous haemorrhage 28.87 22.72 8 18126 346 79725908
Haemodynamic instability 28.85 22.72 27 18107 17355 79708899
Bacteraemia 28.13 22.72 36 18098 32788 79693466
Renal abscess 27.20 22.72 10 18124 1083 79725171
Therapeutic product effect decreased 26.74 22.72 3 18131 163860 79562394
Pulmonary haemorrhage 26.64 22.72 24 18110 14693 79711561
Sinusitis 26.48 22.72 6 18128 195495 79530759
Abdominal pain upper 26.35 22.72 9 18125 223810 79502444
Scopulariopsis infection 26.05 22.72 6 18128 121 79726133
Dehydration 25.91 22.72 12 18122 248175 79478079
Back pain 25.69 22.72 19 18115 304161 79422093
Immunosuppressant drug level increased 25.34 22.72 19 18115 9008 79717246
Hepatic cytolysis 25.21 22.72 31 18103 27120 79699134
Hepatic necrosis 25.20 22.72 19 18115 9081 79717173
Acute graft versus host disease in intestine 25.05 22.72 14 18120 4027 79722227
Disseminated trichosporonosis 24.75 22.72 6 18128 152 79726102
Fungal skin infection 24.67 22.72 16 18118 6020 79720234
Epidermolysis 24.62 22.72 9 18125 959 79725295
Thrombocytopenia 24.36 22.72 122 18012 265137 79461117
Hyperhidrosis 24.15 22.72 3 18131 151489 79574765
Blood bilirubin increased 23.90 22.72 49 18085 66183 79660071
Acute myeloid leukaemia 23.57 22.72 32 18102 30853 79695401
Nephropathy toxic 23.45 22.72 26 18108 20393 79705861
Bacterial infection 23.25 22.72 32 18102 31248 79695006
White blood cell count increased 23.23 22.72 52 18082 74581 79651673
Staphylococcal sepsis 22.77 22.72 22 18112 14704 79711550

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J02AX04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Other antimycotics for systemic use
FDA CS M0519359 Lipopeptides
FDA EPC N0000175507 Echinocandin Antifungal
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
MeSH PA D004791 Enzyme Inhibitors
CHEBI has role CHEBI:35441 antiinfective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Candidiasis of the esophagus indication 20639004 DOID:13146
Candidemia indication 432261003
Intra-Abdominal Candida Abscess indication
Candida Pleural Space Infection indication
Refractory Aspergillosis indication
Candida Peritonitis indication
Oropharyngeal Candidiasis off-label use
Hypokalemia contraindication 43339004
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.55 acidic
pKa2 11.98 acidic
pKa3 13.1 acidic
pKa4 13.77 acidic
pKa5 13.84 acidic
pKa6 10.04 Basic
pKa7 9.05 Basic
pKa8 4.09 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
ATP-binding cassette sub-family G member 2 Transporter IC50 5.22 CHEMBL
Beta-1,3-glucan synthase catalytic subunit 1 Enzyme INHIBITOR IC50 8.89 WOMBAT-PK CHEMBL
1,3-beta-glucan synthase catalytic subunit FksP Enzyme INHIBITOR CHEMBL CHEMBL
1,3-beta-D-glucan synthase catalytic subunit Unclassified IC50 9.62 CHEMBL

External reference:

IDSource
4021254 VUID
N0000148695 NUI
D02501 KEGG_DRUG
179463-17-3 SECONDARY_CAS_RN
4021253 VANDF
4021254 VANDF
C0537894 UMLSCUI
CHEBI:474180 CHEBI
CHEMBL499808 ChEMBL_ID
CHEMBL4297142 ChEMBL_ID
D000077336 MESH_DESCRIPTOR_UI
DB00520 DRUGBANK_ID
7778 INN_ID
F0XDI6ZL63 UNII
16119814 PUBCHEM_CID
140108 RXNORM
15896 MMSL
260563 MMSL
41099 MMSL
d04748 MMSL
009069 NDDF
009070 NDDF
129474002 SNOMEDCT_US
407732005 SNOMEDCT_US
413770001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CANCIDAS HUMAN PRESCRIPTION DRUG LABEL 1 0006-3822 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS NDA 28 sections
CANCIDAS HUMAN PRESCRIPTION DRUG LABEL 1 0006-3822 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS NDA 28 sections
CANCIDAS HUMAN PRESCRIPTION DRUG LABEL 1 0006-3823 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS NDA 28 sections
CANCIDAS HUMAN PRESCRIPTION DRUG LABEL 1 0006-3823 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS NDA 28 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 0781-3421 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 27 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 0781-3423 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 27 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 25021-194 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 31 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 25021-195 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 31 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 63323-356 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS NDA 29 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 63323-358 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS NDA 29 sections
Caspofungin Acetate Human Prescription Drug Label 1 68083-158 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 26 sections
Caspofungin Acetate Human Prescription Drug Label 1 68083-159 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 26 sections
caspofungin acetate HUMAN PRESCRIPTION DRUG LABEL 1 69097-365 INJECTION 5 mg INTRAVENOUS ANDA 23 sections
caspofungin acetate HUMAN PRESCRIPTION DRUG LABEL 1 69097-366 INJECTION 7 mg INTRAVENOUS ANDA 23 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 70860-106 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 28 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 70860-106 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 28 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 70860-107 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 70 mg INTRAVENOUS ANDA 28 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 70860-107 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 70 mg INTRAVENOUS ANDA 28 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 72266-106 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 26 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 72266-106 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 26 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 72266-107 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 26 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 72266-107 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 26 sections
caspofungin acetate HUMAN PRESCRIPTION DRUG LABEL 1 72611-700 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 28 sections
caspofungin acetate HUMAN PRESCRIPTION DRUG LABEL 1 72611-700 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 28 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 72611-702 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 28 sections
Caspofungin Acetate HUMAN PRESCRIPTION DRUG LABEL 1 72611-702 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 28 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 72843-434 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 5 mg INTRAVENOUS ANDA 28 sections
CASPOFUNGIN ACETATE HUMAN PRESCRIPTION DRUG LABEL 1 72843-533 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 7 mg INTRAVENOUS ANDA 28 sections